BridgeBio Oncology Therapeutics (BBOT) investor relations material

Opening remarks and agenda

• The meeting was called to order by the President and CEO, who welcomed shareholders and confirmed the meeting was held in accordance with bylaws and Delaware law.

• Directors, executive team, audit firm representatives, and outside counsel were recognized.

• Shareholders were informed of voting and question procedures, with rules of conduct available in the meeting materials.

Board and executive committee updates

• Two nominees, Frank McCormick and Peter Lebowitz, were nominated for Class I director positions for a three-year term, with no other nominations received.

Corporate governance

• The audit committee, composed entirely of independent directors, appointed Deloitte & Touche as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

• Stockholders were asked to ratify the appointment of Deloitte & Touche as a matter of good governance, though not required by bylaws.